Group 1 - The company has adjusted the 2025 stock option incentive plan, reducing the number of initial grant recipients from 90 to 87 and the number of stock options from 40.8 million to 40 million, while increasing the reserved stock options from 9.2 million to 10 million [1][2] - The adjustments comply with relevant laws and regulations, including the Company Law and Securities Law, and do not harm the interests of the company or its shareholders [1][2] - The first grant date for the stock options is set for August 28, 2025, with an exercise price of 1.66 yuan per share for the 87 eligible recipients [2] Group 2 - All 87 recipients of the stock options meet the qualifications set forth in the incentive plan and have not been deemed inappropriate candidates by regulatory bodies in the past 12 months [2] - The monitoring committee has unanimously agreed that the adjustments to the stock option incentive plan and the initial grant of stock options are legal, compliant, and beneficial for the company's ongoing development [2]

北京铜官盈新文化旅游发展股份有限公司 董事会薪酬与考核委员会关于调整 2025 年股票期权激励计划 相关事项及首次授予股票期权的核查意见 北京铜官盈新文化旅游发展股份有限公司（以下简称"公司"） 董事会薪酬 与考核委员会依据《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》 （以下简称"《证券法》"） 《上市公司股权激励管理办法》 （以 下简称"《管理办法》"）等有关法律、法规和规范性文件以及《北京铜官盈新 文化旅游发展股份有限公司章程》 （以下简称"《公司章程》"）的规定，对公司 调整 2025 年股票期权激励计划相关事项及首次授予股票期权进行了核查，现发表 核查意见如下： 一、关于调整 2025 年股票期权激励计划相关事项的核查意见 鉴于公司激励计划首次授予的激励对象名单中，有 3 名激励对象因岗位调整、 调出公司、个人自愿放弃认购等原因不再纳入激励对象范围，因此，根据激励计 划的有关规定和公司 2025 年第一次临时股东会的授权，董事会对股权激励计划首 次授予激励对象人数及授予权益数量进行调整。本次激励计划拟首次授予的激励 对象由 90 名调整为 87 名，首次授予的股票期权数 ...

Core Viewpoint - The legal opinion letter confirms that the adjustments to the 2025 stock option incentive plan and the initial grant of stock options by Beijing Tongguan Yingxin Cultural Tourism Development Co., Ltd. have received necessary approvals and comply with relevant laws and regulations [9][12]. Summary by Relevant Sections Legal Framework - The law firm has been appointed as a special legal advisor to the company regarding the adjustments to the stock option incentive plan and the initial grant of stock options, in accordance with the Company Law, Securities Law, and other regulatory guidelines [2][4]. Approval Process - The adjustments and initial grants have been approved by the company's shareholders, with over two-thirds of voting rights in favor of the relevant proposals [8]. - The company has publicly disclosed the names and positions of the proposed incentive recipients during the designated public notice period, with no objections received [7][9]. Adjustments to Incentive Recipients - The number of incentive recipients has been adjusted from 90 to 87 due to changes in personnel and voluntary withdrawals [10][12]. - The total number of stock options to be granted in the initial award is 40 million, with an exercise price set at 1.66 yuan per share [12]. Compliance and Conditions - The legal opinion asserts that all conditions for granting stock options have been met, including the absence of disqualifying events for both the company and the incentive recipients [11][12]. - The initial grant date has been determined as August 28, 2025, which aligns with regulatory requirements [11][12]. Conclusion - The legal opinion concludes that the adjustments and initial grants are legally valid and effective, and the company must fulfill its disclosure obligations and complete the necessary registration for the stock options [13].

Core Viewpoint - The company has approved the initial grant of stock options under the 2025 Stock Option Incentive Plan, granting 40 million stock options to 87 eligible participants, with a strike price of 1.66 yuan per option [1][2][10]. Summary by Relevant Sections Stock Option Incentive Plan Overview - The incentive plan involves stock options as the incentive tool, with stock sourced from a directed issuance of A-shares or repurchased shares from the secondary market [1][2]. - The total number of stock options granted is 40 million, distributed among 87 participants, including middle and senior management and key technical personnel [1][2][10]. Granting Conditions and Procedures - The granting conditions have been met as per the plan, and the board has authorized the grant date as August 28, 2025 [1][10]. - The plan has undergone necessary decision-making procedures, including approval from the board and supervisory committee [8][10]. Distribution of Stock Options - The distribution of stock options is as follows: 31.5 million options (63%) to middle management, 9.3 million options (18.6%) to key technical personnel, and 9.2 million options (18.4%) reserved [2][10]. - The total options granted do not exceed 1% of the company's total share capital at the time of the plan's announcement [2][10]. Exercise Conditions and Performance Assessment - The options have a maximum validity of 48 months, with a waiting period of 12 months for the first grant and 24 months for reserved options [4][5]. - Performance targets for the first two years are set at 770 million yuan and 840 million yuan for 2025 and 2026, respectively, with specific conditions for exercising the options based on company performance [5][7]. Financial Impact and Cost Estimation - The estimated total cost for the stock options is 8.0859 million yuan, which will be amortized over the exercise period [13][14]. - The incentive plan is expected to positively impact the company's long-term performance by enhancing employee motivation and operational efficiency [14]. Legal Compliance and Approval - The plan has been reviewed and approved by legal counsel, confirming compliance with relevant laws and regulations [15][17]. - The company has ensured that all participants meet the eligibility criteria set forth in the incentive plan [15][17].

Core Viewpoint - The company has adjusted its 2025 stock option incentive plan, reducing the number of initial grant recipients and the total number of stock options to be granted, while ensuring compliance with relevant regulations and maintaining the plan's overall integrity [1][3][5]. Group 1: Decision Process and Disclosure - The company has followed the necessary decision-making procedures and disclosed information regarding the adjustment of the 2025 stock option incentive plan [1]. - The board and supervisory committee have reviewed and approved the relevant proposals related to the stock option incentive plan [2][3]. Group 2: Adjustments to the Incentive Plan - The number of initial grant recipients has been reduced from 90 to 87 due to reasons such as job changes and voluntary withdrawal [3][5]. - The total number of stock options to be granted has been adjusted from 40.8 million to 40 million, while the reserved stock options have increased from 9.2 million to 10 million [3][5]. Group 3: Impact of Adjustments - The adjustments made to the incentive plan are in accordance with the relevant laws and regulations and will not have a substantial impact on the company's financial status or operational results [4][5]. Group 4: Opinions from Committees - The remuneration and assessment committee, along with the supervisory committee, have expressed their agreement with the adjustments made to the incentive plan [4][5]. Group 5: Legal Opinions - The legal opinion confirms that the adjustments and grants have received the necessary approvals and comply with applicable laws and regulations [5].

Core Points - The company held its 13th meeting of the 9th Board of Directors, where several key resolutions were passed regarding financial reports, fundraising, and investment projects [1][2][3] Financial Reports - The Board approved the 2025 semi-annual report and its summary, with all 9 directors voting in favor [1] - A special report on the management and use of raised funds for the first half of 2025 was also approved unanimously [2] Investment Projects - The Board agreed to invest in a new lithium-ion battery manufacturing base project in Nanjing with a total investment not exceeding RMB 4 billion [3] - Another project for a 20GWh new energy battery base in Wuhu was approved, also with a total investment not exceeding RMB 4 billion [4][5] Related Transactions - The Board approved the addition of expected daily related transactions for 2025, which will be subject to shareholder approval at the next general meeting [2][3] Stock Option Plans - The Board adjusted the exercise price of the 2021 stock option incentive plan from RMB 39.10 to RMB 39.00 per share [6] - The conditions for the third exercise period of the 2021 stock option incentive plan were deemed fulfilled, allowing 733,320 stock options to be exercised by eligible participants [7] - The Board also approved the cancellation of 216,300 stock options that were not exercised due to certain participants not meeting the exercise conditions [8] Employee Stock Ownership Plans - The Board approved adjustments to the fourth employee stock ownership plan, increasing the reserved shares from 2 million to 2.975 million shares [13] - A new fifth employee stock ownership plan was proposed, which aims to enhance employee engagement and company governance [14][15] Governance and Compliance - The Board proposed revisions to several internal management systems to improve compliance and governance [17] - A notice for the 2025 first extraordinary general meeting was approved, scheduled for September 23, 2025 [18]

山东未名生物医药股份有限公司 董事会薪酬与考核委员会关于公司 2025 年股票期权 激励计划相关事项的核查意见 （五）中国证监会认定的其他情形。公司具备实施股权激励计划的主体资格。 二、公司本激励计划所确定的激励对象不存在《管理办法》第八条规定的不 得成为激励对象的以下情形： （一）最近 12 个月内被证券交易所认定为不适当人选； （二）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （三）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； 山东未名生物医药股份有限公司（以下简称"公司"）董事会薪酬与考核委 员会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《深圳证券交易所股票上市规则》（以下简称 "《上市规则》"）、《山东未名生物医药股份有限公司章程》（以下简称"《公 司章程》"）的规定，对《山东未名生物医药股份有限公司 2025 年股票期权激 励计划（草案）》（以下简称"本激励计划"）及其他相关资料进行审核，发表 核查意见如下： ...

证券代码：002581 证券简称：ST未名 公告编号：2025-065 山东未名生物医药股份有限公司 山东未名生物医药股份有限公司(以下简称"公司")第六届董事会第六次会 议于 2025 年 8 月 29 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实际 参加表决董事 11 人，分别为：岳家霖、刘文俊、徐隽雄、周婷、陈星、史晓如、 黄桂源、蔡艳红、张荣富、刘洋、夏阳。董事会会议通知已于 2025 年 8 月 27 日以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召集和召 开符合国家有关法律法规、《董事会议事规则》及《公司章程》的规定。本次会 议审议了如下议案： 二、董事会会议审议情况 （一）审议通过了《关于〈山东未名生物医药股份有限公司 2025 年股票期权 激励计划（草案）〉及其摘要的议案》 为进一步完善公司治理结构，建立、健全公司长期激励与约束机制，倡导公 司与管理层及骨干员工共同持续发展的理念，充分调动董事、高级管理人员、中 层管理人员及核心骨干员工的积极性，有效地将股东利益、公司利益和员工个人 利益结合在一起，提升公司的核心竞争力，确保公司发展战略和经营目标的实现， 公司依 ...

予部分第一个行权期采用自主行权模式的提示性公告》（公告编号：2023-068）， 本激励计划首次授予部分第一个行权期实际可行权期限为自 2023 年 9 月 20 日至 的股票期权数量合计为 1,731.60 万份。自公司董事会审议通过《关于 2022 年股 票期权激励计划首次授予第一个行权期行权条件成就的议案》至办理完成本次自 主行权相关申报登记期间，共有 10 名激励对象因离职而不符合行权条件，其相 应获授的 20 万份股票期权后期将在履行审批程序后予以注销。 第八次会议，会议审议通过了《关于调整 2022 年股票期权激励计划行权价格的 议案》，将本激励计划行权价格由 18.67 元/股调整为 18.57 元/股。 第九次会议，会议审议通过了《关于 2022 年股票期权激励计划首次授予第二个 行权期行权条件成就的议案》和《关于注销 2022 年股票期权激励计划首次授予 部分股票期权的议案》。本激励计划首次授予的股票期权第二个行权期符合行权 条件的激励对象为 1,477 名，可行权的股票期权数量为 1,243.68 万份，行权价格 为 18.57 元/股。同时，由于部分激励对象存在个人绩效考核未完全达标或未 ...

证券代码：002074 证券简称：国轩高科 公告编号：2025-055 期权的第三个行权期符合行权条件的激励对象合计 1,406 名，涉及可行权的股票 期权数量为 942.048 万份（实际行权数量以中国证券登记结算有限责任公司深圳 分公司登记为准），占公司目前总股本的 0.522%，行权价格为 18.47 元/份。 相应的行权手续后方可行权，届时公司将发布提示性公告，敬请投资者注意。 国轩高科股份有限公司（以下简称"公司"） 于2025年8月28日召开第九届董 事会第十三次会议及第九届监事会第十三次会议，审议通过了《关于2022年股票 期权激励计划首次授予第三个行权期行权条件成就的议案》，该事项已经公司 计划》的相关规定，董事会认为公司2022年股票期权激励计划首次授予的股票期 权第三个行权期行权条件已经成就，现将相关事项公告如下： 一、本激励计划已履行的审批程序和披露情况 通过了《关于 <公司 ensp="ensp" 年股票期权激励计划="年股票期权激励计划" 草案="草案"> 及其摘要 的议案》《关 于 <公司 ensp="ensp" 年股票期权激励计划实施考核管理办法="年股票期权激励计划实施考核管理 ...